GlassScriptPhysician profile
John D Rathbun
NPI 1093788192
$2,952.10
in general payments reported to CMS, 2019-2025
25 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $60.30 · 2021: $410 · 2022: $472 · 2023: $557 · 2024: $720 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $799.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $633.57 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $334.37 | 2019-2024 | Xarelto |
| Cvrx, INC. | $204.25 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $201.49 | 2019-2024 | Lifevest |
| Pfizer INC. | $173.98 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $87.87 | 2023-2024 | Inpefa |
| Abiomed | $62.44 | 2024-2025 | Impella |
| Boston Scientific Corporation | $54.84 | 2021-2025 | Watchman Flx |
| Astellas Pharma US INC | $51.93 | 2019-2020 | |
| Amgen INC. | $46.79 | 2019-2020 | |
| Esperion Therapeutics, INC. | $41.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.41 | 2021-2025 | Jardiance |
| Angiodynamics, INC. | $27.78 | 2025 | Alphavac |
| Novo Nordisk INC | $24.85 | 2025 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $22.29 | 2021 | |
| Inspire Medical Systems, INC. | $21.33 | 2025 | Inspire |
| Cardiovascular Systems INC. | $19.04 | 2023 | Diamondback Coronary |
| Merck Sharp & Dohme LLC | $17.64 | 2025 | Verquvo |
| Cleerly, INC. | $17.01 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Bayer Healthcare Pharmaceuticals INC. | $16.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.13 | 2019 | |
| Acist Medical Systems, INC. | $16.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rathbun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.